Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Imunoterapija pri ploščatoceličnem karcinomu glave in vratu - izkušnje iz Slovenije
Authors:ID Plavc, Gaber (Author)
ID Strojan, Primož (Author)
ID Azarija, Jelena (Author)
ID Grašič-Kuhar, Cvetka (Author)
Files:.pdf PDF - Presentation file, download (182,60 KB)
MD5: 8A7C230A6D64826827508DE148643387
 
Language:Slovenian
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Izhodišča: Imunoterapija z zaviralcem imunskih kontrolnih točk nivolumabom, zaviralnim protitelesom proti proteinu programirane celične smrti 1 (PD-1), je za bolnike z neozdravljivo ponovitvijo bolezni ali sistemskimi zasevki ploščatoceličnega karcinoma glave in vratu (P/Z PKGV), pri katerih je bolezen neobčutljiva na preparate platine, pomembna nova možnost zdravljenja. V primerjavi s citostatiki pomembno podaljša njihovo preživetje. Metode: Opravljena je bila retrospektivna analiza zdravljenja z nivolumabom pri slovenskih bolnikih s P/Z PKGV, ki so prejeli prvi odmerek nivolumaba do marca 2020. Zbiranje podatkov je bilo končano septembra 2020. Uporabljene so bile opisne statistične metode in test log-rank. Rezultati: V raziskavo je bilo vključenih 27 bolnikov. Srednji čas sledenja od prve aplikacije nivolumaba do konca opazovanja je bil 7,4 meseca, relativno šestmesečno celokupno preživetje pa 59- odstotno (95-odstotni interval zaupanja pri 41–78 %). Odgovor na zdravljenje je bil pri 85 % bolnikov ocenjen s kliničnim pregledom in rentgenskim slikanjem prsnega koša, pri čemer je bil pri 41 % kot najboljši odgovor ugotovljen delen odgovor na zdravljenje. Imunsko pogojeni neželeni dogodki so se pojavili pri 30 % bolnikov, pri čemer so bili vsi gradusa ≤ 2. En bolnik je bil sočasno z nivolumabom tudi obsevan. Zaključek: Glede na zbrane podatke se je tudi v slovenski populaciji bolnikov s P/Z PKGV zdravljenje z nivolumabom izkazalo za varno. Zaradi kratkega časa sledenja ugotovljene učinkovitosti ni mogoče primerjati z rezultati tujih raziskav. S pričakovano odobritvijo pembrolizumaba bodo zaviralci imunskih kontrolnih točk tudi v Sloveniji dobili mesto v prvem redu zdravljenja P/Z PKGV.
Keywords:rak glave in vratu, imunoterapija, nivolumab
Publication status:Published
Publication version:Version of Record
Year of publishing:2021
Number of pages:str. 6-11
Numbering:Letn. 25, št. 1
PID:20.500.12556/DiRROS-14104 New window
UDC:616-006
ISSN on article:1408-1741
COBISS.SI-ID:66137859 New window
Copyright:by Authors
Publication date in DiRROS:10.06.2021
Views:1214
Downloads:318
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija. strokovni časopis za zdravnike
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.06.2021

Secondary language

Language:English
Title:Immunotherapy for squamous cell carcinoma of the head and neck - experience from Slovenia
Abstract:Background: Immunotherapy with the immune checkpoint inhibitor nivolumab – an inhibitory antibody against programmed death receptor-1 (anti-PD-1) – represents an important new treatment option for patients with an incurable recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) that is unresponsive to platinum-based chemotherapy. It significantly prolongs survival compared to standard chemotherapy. Methods: A retrospective analysis of treatment with nivolumab in patients with R/M HNSCC in Slovenia who received their first dose of nivolumab by March 2020 was performed. Data collection was completed in September 2020. Descriptive statistics and log rank tests were used. Results: Twenty-seven patients entered the study. The median time of follow-up from the first nivolumab application onward was 7.4 months, and the relative six-month overall survival rate was 59% (95% confidence interval 41–78%). In 85% of patients, the response to treatment was evaluated using clinical examination and chest x-ray only. In 41% of patients the partial response to treatment was declared as the best response achieved. Thirty per cent of patients experienced immune-related adverse events, of which all were grade ≤2. In one patient radiotherapy was delivered concurrently with nivolumab. Conclusion: According to the presented results, treatment with nivolumab has also been shown to be safe in Slovenian patients with R/M HNSCC. Due to the short follow-up time, the observed efficacy cannot be compared with the results of foreign studies. With the expected approval of pembrolizumab, immune checkpoint inhibitors will also be given a place in the first line treatment of R/M HNSCC in Slovenia.
Keywords:head and neck cancer, immunotherapy, nivolumab


Archive

niGradiv

Back